Cancer Diagnostic Applications of ENOX2 Proteins

  • D. James Morré
  • Dorothy M. Morré
Chapter

Abstract

That the cancer cell surface-located ENOX2 proteins are produced only by cancer cells and shed into the blood offer an opportunity for cancer detection based on serum analyses including early stages when the cancer is localized and potentially curable. Transcription variants of ENOX2 are well suited as absolute cancer-specific molecular targets for early diagnosis of cancer and recurrent disease. Each major form of human cancer presents with at least one, at most two, characteristic transcript variants of molecular weight and isoelectric point that are specific for the organ of cancer origin. Variants are revealed by two-dimensional gel electrophoresis with detection using a recombinant single chain variable region (scFv antibody specific for ENOX2 transcript variants. As the transcript variants are molecular signature molecules produced only by cancer cells, absent from noncancer cells, and not produced by benign or inflammatory conditions, false positive, in principle, are eliminated. The strategy of early detection combined with early intervention opportunities described in Chap. 11 raises the possibility of a significant paradigm shift in cancer management toward early diagnosis and treatment options vastly different from those currently employed to deal primarily with advanced cancer.

References

  1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariott A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda, MDGoogle Scholar
  2. Bertucci F, Goncalves A (2008) Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol 4:271–287PubMedCrossRefGoogle Scholar
  3. Cho NM, Chueh P-J, Kim C, Caldwell S, Morré DM, Morré DJ (2002) Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol Immunother 51:121–129PubMedCrossRefGoogle Scholar
  4. Chueh P-J, Kim C, Cho N, Morré DM, Morré DJ (2002b) Molecular cloning and characterization of a tumor-associated, growth-related and time-keeping hydroquinone (NADH) oxidase (NOX) of the HeLa cell surface. Biochemistry 41:3732–3741PubMedCrossRefGoogle Scholar
  5. De Luca T, Morré DM, Morré DJ (2010) Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem 110:1504–1511PubMedCrossRefGoogle Scholar
  6. Dnistrian AM, Schwartz MK, Katopodis N, Fracchia AA, Stock CC (1982) Serum lipid-bound sialic acid as a marker in breast cancer. Cancer 50:1815–1819PubMedCrossRefGoogle Scholar
  7. Hostetler B, Kim C (2011) Detecting neoplasia-specific tNOX isoforms. Patent GB2441860Google Scholar
  8. Hostetler B, Weston N, Kim C, Morré DM, Morré DJ (2009) Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase. Clin Proteomics 5:46–51CrossRefGoogle Scholar
  9. Kim C (2011) Single chain pan ECTO-NOX variable region (ScFv) antibody, coding sequence and methods. Patent GB2442553BGoogle Scholar
  10. Lengle EE (1979) Increased levels of lipid-bound sialic acid in thymic lymphocytes and plasma from leukemic AKR/J mice. J Natl Cancer Inst 62:1564–1579Google Scholar
  11. Morré DJ (1995a) NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-4-methylphenylsulfonyl-N′-4-chlorophenylurea LY181984 at an external site. Biochim Biophys Acta 1240:201–208PubMedCrossRefGoogle Scholar
  12. Morré DJ (1998c) NADH oxidase: a multifunctional ectoprotein of the eukaryotic cell surface. In: Asard H, Bérczi A, Caubergs R (eds) Plasma membrane redox systems and their role in biological stress and disease. Kluwer Academic, Dordrecht, The Netherlands, pp 121–156Google Scholar
  13. Morré DJ, Morré DM (2003a) Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative disease. Free Radic Res 37:795–808PubMedCrossRefGoogle Scholar
  14. Morré DJ, Reust T (1997) A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-methylphenylsulfonyl-N′-4-chlorophenylurea LY181984 specific to sera from cancer patients. J Bioenerg Biomembr 29:281–289PubMedCrossRefGoogle Scholar
  15. Morré DJ, Chueh P-J, Morré DM (1995b) Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci U S A 92:1831–1835PubMedCrossRefGoogle Scholar
  16. Morré DJ, Wu L-Y, Morré DM (1995i) The antitumor sulfonylurea N-4-methylphenylsulfonylurea-N′-chlorophenylurea LY181984 inhibits NADH oxidase activity of HeLa plasma membranes. Biochim Biophys Acta 1240:11–17PubMedCrossRefGoogle Scholar
  17. Morré DJ, Wilkinson FE, Kim C, Cho N, Lawrence J, Morré DM, McClure D (1996c) Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media. Biochim Biophys Acta 1280:197–206PubMedCrossRefGoogle Scholar
  18. Morré DJ, Caldwell S, Mayorga A, Wu L-Y, Morré DM (1997a) NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients. Arch Biochem Biophys 342:224–230PubMedCrossRefGoogle Scholar
  19. Morré DJ, Kim C, Paulik M, Morré DM, Faulk WP (1997c) Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? J Bioenerg Biomembr 29:269–280PubMedCrossRefGoogle Scholar
  20. Morré DJ, Bridge A, Wu L-Y, Morré DM (2000a) Preferential inhibition by (−)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochem Pharmacol 60:937–946PubMedCrossRefGoogle Scholar
  21. Morré DJ, Pennington KL, Hignite H, Orvis H, Schwartzentruber DJ, Tang X, Morré DM (2005) Detection of blood-borne cancer using polymerase chain reaction for tNOX messenger RNA. In: Abstracts, 97th annual meeting, American Association for Cancer Research, Washington, DC, 1–5 April 2006. Abstract No. 5684, pp 1336–1337Google Scholar
  22. Morré DJ, Tang X, Morré DM, Pennington KL, Hignite H, Orvis H, Schwartzentruber DJ (2006b) RTPCR detection of cancer cells in blood based in presence of a tNOX splice variant mRNA. In: Abstracts, Fourth Early Detection Research Network (EDRN) scientific workshop, 20–22 March 2006, Philadelphia, PA, p 60Google Scholar
  23. Morré DJ, Hostetler B, Weston N, Kim C, Morré DM (2009a) Cancer type-specific tNOX isoforms: a putative family of redox protein splice variants with cancer diagnostic and prognostic potential. Biofactors 34:201–207CrossRefGoogle Scholar
  24. Morré DJ, McClain N, Wu L-Y, Kelly G, Morré DM (2009b) Phenoxodiol treatment alters the subsequent response of tNOX and growth of HeLa cells to paclitaxel and cis-platin. Mol Biotechnol 42:100–109PubMedCrossRefGoogle Scholar
  25. Navarrete-Montalvo D, Gonzalez MN, Montalyo VMT, Jimenez AA, Echiburu-Chau C, Calaf GM (2008) Patterns of recurrence and survival in breast cancer. Oncol Rep 20:531–535PubMedGoogle Scholar
  26. Petro R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br Med J 321:323–329CrossRefGoogle Scholar
  27. Portoukalian J, Zwingelstein G, Abdul-Malak N, Dore JF (1978) Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun 85:916–920PubMedCrossRefGoogle Scholar
  28. Rim A, Chellman-Jeffers M (2008) Trends in breast cancer screening and diagnosis. Cleve Clin J Med 75:S2–S9PubMedCrossRefGoogle Scholar
  29. Sallay SL, Prosise WN, Morré DJ, Matyas GR (1986) Ganglioside and PCA sialic acid serum levels in cancer. Cancer J 1:124–129Google Scholar
  30. Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ (2007) Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. Biochemistry 46:12337–12346PubMedCrossRefGoogle Scholar
  31. Tang X, Morré DJ, Morré DM (2008) Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein. Oncol Res 16:557–567CrossRefGoogle Scholar
  32. Weinberg RA (2007) The biology of cancer, Fig. 11.1, p. 400. Courtesy of Hong, W. K., compiled from SEER Cancer Statistics Review, Garland Science, Oxford
  33. Wilkinson FE, Kim C, Cho N, Chueh P-J, Leslie S, Moya-Camarena S, Wu L-Y, Morré DM, Morré DJ (1996) Isolation and identification of a protein with capsaicin-inhibited NADH oxidase activity from culture media conditioned by growth of HeLa cells. Arch Biochem Biophys 336:275–282PubMedCrossRefGoogle Scholar
  34. Yadav BS, Sharma SC, Singh R, Singh G (2007) Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther 3:75–80PubMedCrossRefGoogle Scholar
  35. Yantiri F, Morré DJ (2001) Isolation and characterization of a tumor-associated NADH oxidase (tNOX) from the HeLa cell surface. Arch Biochem Biophys 391:149–159PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • D. James Morré
    • 1
  • Dorothy M. Morré
    • 1
  1. 1.Mor-NuCo, LLCPurdue Research ParkWest LafayetteUSA

Personalised recommendations